- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07946913
A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Treatment With H1 Antihistamines
A Multicenter, Randomized, Double-Blind, Active-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Treatment With H1 Antihistamines
This is a multicenter, randomized, double-blind, active-controlled Phase III clinical study to evaluate the safety and efficacy of LP-003 injection in patients with chronic spontaneous urticaria who remain symptomatic despite treatment with H1 antihistamines.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 3
Contactos e Locais
Contato de estudo
- Nome: Jie Yang
- Número de telefone: +8621-58372390
- E-mail: yangj@longbiopharma.com
Locais de estudo
-
-
-
Beijing, China
- Peking Union Medical College Hospital
-
Contato:
- Yuxiang Zhi
- Número de telefone: +8610-69151188
- E-mail: yuxiang_zhi@126.com
-
Shenyang, China
- The First Affiliated Hospital of China Medical University
-
Contato:
- Xinghua Gao
- Número de telefone: +8624-83282524
- E-mail: Gaobarry@hotmail.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Have the capacity to understand the study and voluntarily signs the informed consent form (ICF);
- Male or female participant must be 12 to 75 years old at the time of ICF signature;
- Duration of chronic spontaneous urticaria (CSU) ≥ 6 months prior to screening;
- Presence of pruritus and wheals for at least 6 consecutive weeks before screening despite treatment with H1-AH;
- Participants have been on a stable dose of second-generation H1-AH as specified in the protocol for ≥2 weeks prior to randomization and within the 7 days before randomization, the UAS7( range 0-42) ≥16 and ISS7(range 0-21) ≥8;
- Participants must not miss UAS scores for more than one day within the 7 days prior to randomization, and are willing and able to complete daily symptom diaries during the study period.
- Female participants of childbearing potential, and male participants (and their female partners), must use one or more effective contraceptive measures from the screening period until at least 6 months after the last administration of investigational product. Participants must have no plans for pregnancy, sperm donation or oocyte donation from screening until at least 6 months after the last dose of investigational product.
Exclusion Criteria:
- The subject has a primary or sole trigger for chronic urticaria (chronic Induced urticaria), including artificial urticaria (Symptomatic Dermographism), cold, heat, sun, pressure, delayed pressure, water, cholinergic, or contact urticaria;
- Other medical conditions accompanied by symptoms of urticaria or angioedema including, but not limited to, urticarial vasculitis, mastocytosis, pigmented urticaria, erythema multiforme, , hereditary or acquired angioedema, etc;
- Any other dermatologic condition with chronic itching, such as atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis, which in the judgment of the Investigator may affect the evaluation of the study and the results of the study;
- Body weight < 40 kg
- Not enough washing-out period for previous therapy before randomization.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: LP-003 group
Participants received LP-003 subcutaneously during the 48-week treatment period |
s.c. injection |
|
Comparador Ativo: Omalizumab group
Participants received omalizumab subcutaneously during the 48-week treatment period |
s.c. injection |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change from baseline in weekly Urticaria Activity Score (UAS7) at week 12
Prazo: Week 12
|
The UAS7 is a composite score derived from the ISS7 and the HSS7, i.e., the sum of ISS7 and HSS7, ranging from 0 to 42 points. UAS7 = 0 indicates complete resolution of urticaria. |
Week 12
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change from baseline in UAS7 at each assessment visit (excluding Week 12)
Prazo: up to approximately 56 weeks
|
up to approximately 56 weeks
|
|
|
The proportion of participants with UAS7 = 0 at each assessment visit
Prazo: up to approximately 56 weeks
|
up to approximately 56 weeks
|
|
|
The proportion of participants with UAS7 ≤ 6at each assessment visit
Prazo: up to approximately 56 weeks
|
up to approximately 56 weeks
|
|
|
Change From Baseline in weekly hives severity score (HSS7) at each assessment visit.
Prazo: up to approximately 56 weeks
|
The HSS7 is the sum of daily HSS scores over the 7 days prior to the visit, ranging from 0 to 21 points. HSS7 = 0 indicates complete resolution of hives. |
up to approximately 56 weeks
|
|
Change From Baseline in weekly itch severity score ( ISS7) at each assessment visit.
Prazo: Time Frame: up to approximately 56 weeks
|
The ISS7 is the sum of daily ISS scores over the 7 days prior to the visit, ranging from 0 to 21 points. ISS7 = 0 indicates complete resolution of itch. |
Time Frame: up to approximately 56 weeks
|
|
Change From Baseline in weekly angloedema activity score (AAS7) at each assessment visit.
Prazo: Time Frame: up to approximately 56 weeks
|
The AAS7 is the sum of the daily AAS scores over the 7 days prior to the visit, ranging from 0 to 105 points. AAS7 = 0 indicates no angioedema. |
Time Frame: up to approximately 56 weeks
|
|
Change From Baseline in Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) at each assessment visit
Prazo: up to approximately 56 weeks
|
The scale consists of 23 items. Each item is scored from 1 to 5 points. The total score is transformed to a scale ranging from 0 to 100, with higher scores indicating a greater impact of the disease on patients' quality of life |
up to approximately 56 weeks
|
|
The incidence of adverse events during the study
Prazo: up to approximately 56 weeks
|
Incidence and severity of AE from first dose to end of study are recorded |
up to approximately 56 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Xinghua Gao, First Hospital of China Medical University
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Processos Patológicos
- Doença crônica
- Atributos da doença
- Doenças do sistema imunológico
- Hipersensibilidade, Imediata
- Hipersensibilidade
- Doenças de pele
- Urticária
- Doenças de Pele, Vasculares
- Condições Patológicas, Sinais e Sintomas
- Doenças da Pele e do Tecido Conjuntivo
- Urticária Crônica
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Anticorpos, monoclonais, humanizados
- Anticorpos, monoclonais
- Anticorpos
- Imunoglobulinas
- Imunoproteínas
- Proteínas sanguíneas
- Globulinas de soro
- Globulins
- Anticorpos, anti-idiotípicos
- Omalizumabe
Outros números de identificação do estudo
- P10-LP003-14
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .